Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Ernexa Therapeutics (ERNA) over the last 15 years, with Q3 2025 value amounting to $26000.0.

  • Ernexa Therapeutics' Cash from Financing Activities fell 9933.11% to $26000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year decrease of 3655.24%. This contributed to the annual value of $6.3 million for FY2024, which is 6218.89% down from last year.
  • Latest data reveals that Ernexa Therapeutics reported Cash from Financing Activities of $26000.0 as of Q3 2025, which was down 9933.11% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, Ernexa Therapeutics' Cash from Financing Activities registered a high of $12.0 million during Q1 2022, and its lowest value of -$22000.0 during Q2 2024.
  • For the 5-year period, Ernexa Therapeutics' Cash from Financing Activities averaged around $4.0 million, with its median value being $2.3 million (2025).
  • Per our database at Business Quant, Ernexa Therapeutics' Cash from Financing Activities surged by 14223333.33% in 2023 and then plummeted by 10705.13% in 2024.
  • Quarter analysis of 5 years shows Ernexa Therapeutics' Cash from Financing Activities stood at $9.9 million in 2021, then decreased by 23.63% to $7.6 million in 2022, then increased by 1.46% to $7.7 million in 2023, then plummeted by 86.89% to $1.0 million in 2024, then plummeted by 97.43% to $26000.0 in 2025.
  • Its last three reported values are $26000.0 in Q3 2025, $4.9 million for Q2 2025, and $2.3 million during Q1 2025.